A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer Meeting Abstract

  

Authors:	Konner, J. A.; Fallon, K.; Pezzuli, S.; Iasonos, A.; Sabbatini, P.; Hensley, M.; Chiang, A.; Tew, W.; Spriggs, D.; Aghajanian, C.
Abstract Title:	A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer
Meeting Title:	43rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	25
Issue:	18 Suppl.
Meeting Dates:	2007 Jun 1-5
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2007-06-20
Start Page:	279s
Language:	English
ACCESSION:	WOS:000455043701306
PROVIDER:	wos
DOI:	10.1200/jco.2007.25.18_suppl.5523
Notes:	Meeting Abstract: 5523 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/141650